BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 21971588)

  • 1. The small molecule TGF-β signaling inhibitor SM16 synergizes with agonistic OX40 antibody to suppress established mammary tumors and reduce spontaneous metastasis.
    Garrison K; Hahn T; Lee WC; Ling LE; Weinberg AD; Akporiaye ET
    Cancer Immunol Immunother; 2012 Apr; 61(4):511-21. PubMed ID: 21971588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An orally active small molecule TGF-beta receptor I antagonist inhibits the growth of metastatic murine breast cancer.
    Rausch MP; Hahn T; Ramanathapuram L; Bradley-Dunlop D; Mahadevan D; Mercado-Pimentel ME; Runyan RB; Besselsen DG; Zhang X; Cheung HK; Lee WC; Ling LE; Akporiaye ET
    Anticancer Res; 2009 Jun; 29(6):2099-109. PubMed ID: 19528470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. STAT3 Signaling Is Required for Optimal Regression of Large Established Tumors in Mice Treated with Anti-OX40 and TGFβ Receptor Blockade.
    Triplett TA; Tucker CG; Triplett KC; Alderman Z; Sun L; Ling LE; Akporiaye ET; Weinberg AD
    Cancer Immunol Res; 2015 May; 3(5):526-35. PubMed ID: 25627655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer.
    Guo Z; Wang X; Cheng D; Xia Z; Luan M; Zhang S
    PLoS One; 2014; 9(2):e89350. PubMed ID: 24586709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic blockade of transforming growth factor-beta signaling augments the efficacy of immunogene therapy.
    Kim S; Buchlis G; Fridlender ZG; Sun J; Kapoor V; Cheng G; Haas A; Cheung HK; Zhang X; Corbley M; Kaiser LR; Ling L; Albelda SM
    Cancer Res; 2008 Dec; 68(24):10247-56. PubMed ID: 19074893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity.
    Redmond WL; Linch SN; Kasiewicz MJ
    Cancer Immunol Res; 2014 Feb; 2(2):142-53. PubMed ID: 24778278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blockade of TGF-β signaling to enhance the antitumor response is accompanied by dysregulation of the functional activity of CD4
    Polanczyk MJ; Walker E; Haley D; Guerrouahen BS; Akporiaye ET
    J Transl Med; 2019 Jul; 17(1):219. PubMed ID: 31288845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-OX40 Antibody Directly Enhances The Function of Tumor-Reactive CD8
    Peng W; Williams LJ; Xu C; Melendez B; McKenzie JA; Chen Y; Jackson HL; Voo KS; Mbofung RM; Leahey SE; Wang J; Lizee G; Tawbi HA; Davies MA; Hoos A; Smothers J; Srinivasan R; Paul EM; Yanamandra N; Hwu P
    Clin Cancer Res; 2019 Nov; 25(21):6406-6416. PubMed ID: 31371342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative analysis of IFN-gamma B7.1 and antisense TGF-beta gene transfer on the tumorigenicity of a poorly immunogenic metastatic mammary carcinoma.
    Wu RS; Kobie JJ; Besselsen DG; Fong TC; Mack VD; McEarchern JA; Akporiaye ET
    Cancer Immunol Immunother; 2001 Jul; 50(5):229-40. PubMed ID: 11499806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice.
    Linch SN; Kasiewicz MJ; McNamara MJ; Hilgart-Martiszus IF; Farhad M; Redmond WL
    Proc Natl Acad Sci U S A; 2016 Jan; 113(3):E319-27. PubMed ID: 26729864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancing the Generation of Eomes
    Emerson DA; Rolig AS; Redmond WL
    Cancer Immunol Res; 2021 Apr; 9(4):430-440. PubMed ID: 33593794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frontline Science: OX40 agonistic antibody reverses immune suppression and improves survival in sepsis.
    Unsinger J; Walton AH; Blood T; Tenney DJ; Quigley M; Drewry AM; Hotchkiss RS
    J Leukoc Biol; 2021 Apr; 109(4):697-708. PubMed ID: 33264454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intratumoral delivery of encapsulated IL-12, IL-18 and TNF-alpha in a model of metastatic breast cancer.
    Sabel MS; Su G; Griffith KA; Chang AE
    Breast Cancer Res Treat; 2010 Jul; 122(2):325-36. PubMed ID: 19802695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FcγRIIB engagement drives agonistic activity of Fc-engineered αOX40 antibody to stimulate human tumor-infiltrating T cells.
    Campos Carrascosa L; van Beek AA; de Ruiter V; Doukas M; Wei J; Fisher TS; Ching K; Yang W; van Loon K; Boor PPC; Rakké YS; Noordam L; Doornebosch P; Grünhagen D; Verhoef K; Polak WG; IJzermans JNM; Ni I; Yeung YA; Salek-Ardakani S; Sprengers D; Kwekkeboom J
    J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32900860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. OX40 ligation enhances primary and memory cytotoxic T lymphocyte responses in an immunotherapy for hepatic colon metastases.
    Pan PY; Zang Y; Weber K; Meseck ML; Chen SH
    Mol Ther; 2002 Oct; 6(4):528-36. PubMed ID: 12377195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PLGA-nanoparticle mediated delivery of anti-OX40 monoclonal antibody enhances anti-tumor cytotoxic T cell responses.
    Chen M; Ouyang H; Zhou S; Li J; Ye Y
    Cell Immunol; 2014 Feb; 287(2):91-9. PubMed ID: 24487032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor.
    Gough MJ; Ruby CE; Redmond WL; Dhungel B; Brown A; Weinberg AD
    Cancer Res; 2008 Jul; 68(13):5206-15. PubMed ID: 18593921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Agonist OX40 immunotherapy improves survival in glioma-bearing mice and is complementary with vaccination with irradiated GM-CSF-expressing tumor cells.
    Jahan N; Talat H; Curry WT
    Neuro Oncol; 2018 Jan; 20(1):44-54. PubMed ID: 29016879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapy of established tumors by antibodies targeting immune activating and suppressing molecules.
    Takeda K; Kojima Y; Uno T; Hayakawa Y; Teng MW; Yoshizawa H; Yagita H; Gejyo F; Okumura K; Smyth MJ
    J Immunol; 2010 May; 184(10):5493-501. PubMed ID: 20400706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual anti-OX40/IL-2 therapy augments tumor immunotherapy via IL-2R-mediated regulation of OX40 expression.
    Redmond WL; Triplett T; Floyd K; Weinberg AD
    PLoS One; 2012; 7(4):e34467. PubMed ID: 22496812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.